Geode Capital Management
LIMN

Geode Capital Management’s Liminatus Pharma LIMN Stock Holding History

Geode Capital Management’s Portfolio LIMN Stock Details LIMN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.3K Buy
138,418
+20,635
+18% +$3.56K ﹤0.01% 4395
2026
Q1 		$20.2K Buy
117,783
+52,732
+81% +$28.1K ﹤0.01% 4447
2025
Q4 		$39.7K Buy
65,051
+1,317
+2% +$1.46K ﹤0.01% 4274
2025
Q3 		$106K Sell
63,734
-107
-0.2% -$462 ﹤0.01% 4117
2025
Q2 		$712K Buy
+63,841
New +$717K ﹤0.01% 3440

Other funds holding LIMN

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $12.2B AUM 47.93% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management's LIMN Position: Q2 2026 in Review

Geode Capital Management increased its Liminatus Pharma (LIMN) stake by 18% in Q2 2026, buying an estimated $3.56K and bringing the position to 138,418 shares worth $15.3K. The position accounts for ﹤0.01% of the portfolio, ranked #4395.

Geode Capital Management first reported a position in LIMN in Q2 2025 and has held it in 5 quarters since. The position peaked at $712K in Q2 2025. 9 funds tracked by Wall St. Rank hold LIMN as of Q2 2026.

  • Geode Capital Management held 138,418 shares of Liminatus Pharma worth $15.3K as of Q2 2026.
  • Geode Capital Management bought 20,635 Liminatus Pharma shares in Q2 2026, an estimated $3.56K.
  • Liminatus Pharma made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #4395 holding.
  • Geode Capital Management first reported a position in Liminatus Pharma in Q2 2025 and has held it in 5 quarters since.
  • Geode Capital Management's Liminatus Pharma position peaked at $712K in Q2 2025.
  • 9 funds tracked by Wall St. Rank held Liminatus Pharma as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.